Pharmacogenetics and Antineoplastic Therapies

摘要: The genome of cancer cells differs from that the host cell which it arises. These changes in molecular pathways drive cellular proliferation and ultimately tumour growth progression. As a result, there has been shift categorising tumours solely based on their tissue origin histology to consideration profiles. This transformation led current breadth treatments available, including largely targeted therapies. When individualising therapy, is essential evaluate expected individual drug exposure, risk for toxicity, efficacy; however, large heterogeneity response antineoplastic therapies exists across human population. Dose-limiting toxicities often lead dose reductions delays even potentially curative setting. It therefore imperative clinicians be able identify patients most likely benefit treatment those at an increased toxicity. chapter will focus pharmacogenetic associations therapies, prospective identification clinically validated and/or utilised germ-line somatic biomarkers, maximising clinical efficacy minimising